Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AMG 509 in Metastatic Castration-Resistant Prostate Cancer
jRCT2031200384Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Mar 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of xaluritamig in metastatic castration-resistant prostate cancer (mCRPC) (10 arms), sponsored by Amgen. Primary endpoints: Incidence of Treatment-emergent Adverse Events (Parts 1-5 and 7), Incidence of Treatment-related Adverse Events (Parts 1-5 and 7) and 5 more. Started Mar 2020; status: recruiting.
02
Drugs
xaluritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031200384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200384.